Roche under CCI scanner for drug
Mumbai, April 26: India’s antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anticompetitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.
Trastuzumab has been a mainstay of Roche’s profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 per cent discount to the original.
India’s Biocon and US firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.
India, with among the highest number of cancer patients in the world, is a big market for trastuzumab, which is indicated to treat certain forms of breast and gastric cancer.
Roche first launched the drug in India in 2002 and sells it for about `75,000 for a 440 mg vial.
In an interim order released on Tuesday, the CCI said it found merit in Biocon and Mylan’s arguments, and ordered its director general to conduct a “detailed investigation” and submit a report within 60 days.
“Roche adheres to all applicable laws and regulations in countries where it operates,” Roche spokeswoman Shilpika Das said in a statement.
“We are fully committed to cooperating with the authorities in India.”
Biocon said it welcomed the CCI’s order, which although not final, but the investigation could result in penalties, a lawyer at the Delhi High Court, who declined to be named, said.
Roche, which has been engaged in a legal tussle with Biocon and Mylan since 2014, has the option of filing a petition to contest the order, the lawyer added.
In their complaint, Biocon and Mylan allege Roche wrote to doctors, hospitals, and state and federal regulators, misleading them about the safety of efficacy of the biosimilar versions.
BIOCON AND US firm Mylan filed a complaint with the CCI last year
IN THE COMPLAINT, both firms allege Roche wrote to doctors, hospitals, and state and federal regulators to mislead them